Literature DB >> 27198052

Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.

F Cervantes-Gomez1, V Kumar Patel1, P Bose2, M J Keating2, V Gandhi1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27198052      PMCID： PMC5739032          DOI： 10.1038/leu.2016.129

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells.

Authors:  S Nisitani; A B Satterthwaite; K Akashi; I L Weissman; O N Witte; M I Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.

Authors:  Fabiola Cervantes-Gomez; Betty Lamothe; Jennifer A Woyach; William G Wierda; Michael J Keating; Kumudha Balakrishnan; Varsha Gandhi
Journal:  Clin Cancer Res       Date:  2015-03-31       Impact factor: 12.531

Review 3.  CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.

Authors:  Jan A Burger; Thomas J Kipps
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

4.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Authors:  Ranjana H Advani; Joseph J Buggy; Jeff P Sharman; Sonali M Smith; Thomas E Boyd; Barbara Grant; Kathryn S Kolibaba; Richard R Furman; Sara Rodriguez; Betty Y Chang; Juthamas Sukbuntherng; Raquel Izumi; Ahmed Hamdy; Eric Hedrick; Nathan H Fowler
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

Review 5.  The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function.

Authors:  D J Rawlings; O N Witte
Journal:  Semin Immunol       Date:  1995-08       Impact factor: 11.130

6.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Authors:  Jan A Burger; Alessandra Tedeschi; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Nancy L Bartlett; Jianyong Li; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Ann Janssens; Fritz Offner; Jiří Mayer; Michael O'Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Constantine S Tam; Deepali Suri; Mei Cheng; Fong Clow; Lori Styles; Danelle F James; Thomas J Kipps
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

7.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

Review 8.  Targeting Bruton's tyrosine kinase in B cell malignancies.

Authors:  Rudi W Hendriks; Saravanan Yuvaraj; Laurens P Kil
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

9.  BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia.

Authors:  S-S Chen; B Y Chang; S Chang; T Tong; S Ham; B Sherry; J A Burger; K R Rai; N Chiorazzi
Journal:  Leukemia       Date:  2015-11-09       Impact factor: 11.528
  9 in total
  13 in total

1.  Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.

Authors:  Sigrid S Skånland; Anthony R Mato
Journal:  Blood Adv       Date:  2021-01-12

2.  Ibrutinib's off-target mechanism: cause for dose optimization.

Authors:  Sara M Zimmerman; Cody J Peer; William D Figg
Journal:  Cancer Biol Ther       Date:  2021-10-10       Impact factor: 4.875

3.  Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.

Authors:  Neeraj Jain; Satishkumar Singh; Georgios Laliotis; Amber Hart; Elizabeth Muhowski; Kristyna Kupcova; Tereza Chrbolkova; Tamer Khashab; Sayan Mullick Chowdhury; Anuvrat Sircar; Fazal Shirazi; Ram Kumar Singh; Lapo Alinari; Jiangjiang Zhu; Ondrej Havranek; Philip Tsichlis; Jennifer Woyach; Robert Baiocchi; Felipe Samaniego; Lalit Sehgal
Journal:  Blood Adv       Date:  2020-09-22

4.  Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.

Authors:  Prithviraj Bose; Varsha V Gandhi; Michael J Keating
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-11       Impact factor: 4.481

5.  FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia.

Authors:  Vaclav Seda; Eva Vojackova; Laura Ondrisova; Lenka Kostalova; Sonali Sharma; Tomas Loja; Gabriela Mladonicka Pavlasova; Daniel Zicha; Marie Kudlickova Peskova; Jan Krivanek; Kvetoslava Liskova; Leos Kren; Vladimir Benes; Katerina Musilova Litzmanova; Marek Borsky; Jan Oppelt; Jan Verner; Sarka Pospisilova; Yvona Brychtova; Anna Panovska; Zhi Tan; Shuxing Zhang; Michael Doubek; Katerina Amruz Cerna; Jiri Mayer; Marek Mraz
Journal:  Blood       Date:  2021-09-02       Impact factor: 22.113

Review 6.  Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas.

Authors:  Bhawana George; Sayan Mullick Chowdhury; Amber Hart; Anuvrat Sircar; Satish Kumar Singh; Uttam Kumar Nath; Mukesh Mamgain; Naveen Kumar Singhal; Lalit Sehgal; Neeraj Jain
Journal:  Cancers (Basel)       Date:  2020-05-22       Impact factor: 6.639

7.  Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells.

Authors:  Subir Roy Chowdhury; Cheryl Peltier; Sen Hou; Amandeep Singh; James B Johnston; Spencer B Gibson; Aaron Marshall; Versha Banerji
Journal:  Cancers (Basel)       Date:  2021-01-19       Impact factor: 6.639

8.  A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.

Authors:  Lisa S Chen; Prithviraj Bose; Nichole D Cruz; Yongying Jiang; Qi Wu; Philip A Thompson; Shuju Feng; Michael H Kroll; Wei Qiao; Xuelin Huang; Nitin Jain; William G Wierda; Michael J Keating; Varsha Gandhi
Journal:  Blood       Date:  2018-09-25       Impact factor: 25.476

Review 9.  Recent therapeutic advances in chronic lymphocytic leukemia.

Authors:  Prithviraj Bose; Varsha Gandhi
Journal:  F1000Res       Date:  2017-10-31

10.  BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.

Authors:  Stefania Fiorcari; Rossana Maffei; Daniela Vallerini; Lydia Scarfò; Patrizia Barozzi; Monica Maccaferri; Leonardo Potenza; Paolo Ghia; Mario Luppi; Roberto Marasca
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.